Abstract

Objective

To access the surgical and oncological outcomes of simultaneous thulium laser enucleation of bladder tumor (ThuLEBT) and thulium laser enucleation of prostate (ThuLEP) in patients with non-muscle invasive bladder tumor (NMIBC) and benign prostatic hyperplasia (BPH).

Patients and methods

Between June 2009 and June 2017, 118 men with NMIBC who underwent simultaneous ThuLEBT and ThuLEP and fulfilled the inclusion criteria were matched with 118 patients who received ThuLEBT alone. Clinicopathological parameters, surgical outcome data and oncological outcomes were retrospectively analyzed and compared.

Results

The patients who underwent simultaneous ThuLEBT and ThuLEP experienced a longer length of operation time (70.4 vs. 25.5 min; p < 0.001), but there were no statistically significant differences in catheterization period, hospital stay and complication between the two groups. At a mean follow-up of 58.7 and 55.8 months in ThuLEBT/ThuLEP group and ThuLEBT group, no significant differences in overall recurrence rates, progression rates, recurrence in the bladder neck/prostatic fossa and mean elapsed time to recurrence were detected. The 5-year recurrence-free probability was 73.2% for ThuLEBT/ThuLEP and 69.2% for ThuLEBT (p = 0.361).

Conclusions

Our results indicate that simultaneous ThuLEBT and ThuLEP can be safely performed without increasing the surgical risk and the risk of tumor recurrence and progression in patients with NMIBC and BPH, and it may be preferred alternative for select patients.

中文翻译：

---

非肌肉浸润性膀胱肿瘤和良性前列腺增生患者膀胱肿瘤和前列腺同时铥激光摘除术的结果：配对比较与长期随访

摘要

客观的

获得同时铥激光膀胱肿瘤摘除术 (ThuLEBT) 和前列腺铥激光摘除术 (ThuLEP) 在非肌肉浸润性膀胱肿瘤 (NMIBC) 和良性前列腺增生 (BPH) 患者中的手术和肿瘤学结果。

患者和方法

2009 年 6 月至 2017 年 6 月期间，118 名同时接受 ThuLEBT 和 ThuLEP 并符合纳入标准的 NMIBC 男性与 118 名仅接受 ThuLEBT 的患者相匹配。回顾性分析和比较临床病理参数、手术结果数据和肿瘤学结果。

结果

同时接受 ThuLEBT 和 ThuLEP 的患者的手术时间更长（70.4 分钟 vs. 25.5 分钟；p  < 0.001），但两组在导尿时间、住院时间和并发症方面无统计学差异。ThuLEBT/ThuLEP 组和 ThuLEBT 组的平均随访时间分别为 58.7 和 55.8 个月，总体复发率、进展率、膀胱颈/前列腺窝复发率和平均复发时间均未检测到显着差异。ThuLEBT/ThuLEP 的 5 年无复发概率为 73.2%，ThuLEBT 为 69.2%（p  = 0.361）。

结论

我们的结果表明，同时 ThuLEBT 和 ThuLEP 可以安全地进行，而不会增加 NMIBC 和 BPH 患者的手术风险和肿瘤复发和进展的风险，并且它可能是特定患者的首选替代方案。